They identified inactivating mutations of the TET2 gene in about 15% of patients with various myeloid malignancies, such as MDS (19%), myeloproliferative disorders (12%), secondary AML (24%) and chronic myelomonocytic leukemia (CMML) (22%) [11]. This evidence concerns the gene TET2 and chronic myelomonocytic leukemia.